Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting.

被引：0
|
作者：
Mu, Yuxin
Meng, Yanchun
Zhang, Jian
机构：
[1] Fudan Univ, Fudan Univ Shanghai Canc Ctr, Dept Med Oncol, Shanghai Med Coll,Dept Oncol, Shanghai, Peoples R China
[2] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13013
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China
    Liu, Xiaoyu
    Zhang, Peng
    Li, Chao
    Song, Xiang
    Liu, Zhaoyun
    Shao, Wenna
    Li, Sumei
    Wang, Xinzhao
    Yu, Zhiyong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] Effectiveness and safety of inetetamab plus pyrotinib plus vinorelbine in ≥second-line treatment of HER2-positive metastatic breast cancer
    Wu, Fan
    Chen, Mulan
    Huang, Weiwei
    Wang, Lili
    Li, Nani
    Wu, Xiufeng
    Chen, Xinhua
    Hong, Yi
    Lin, Lin
    Chen, Kan
    Liu, Jian
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Effectiveness and safety of vinorelbine plus inetetamab plus pyrotinib in ≥second-line treatment of HER2-positive metastatic breast cancer
    Fan, W.
    ANNALS OF ONCOLOGY, 2023, 34 : S364 - S364
  • [4] Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study
    Wang, Tao
    Zhang, Pin
    Di, Lijun
    Wang, Xiaojia
    Yang, Junlan
    Tong, Zhongsheng
    Liu, Jian
    Feng, Jifeng
    Liu, Donggeng
    Yu, Qitao
    Liu, Yunpeng
    Yu, Hao
    Jiang, Zefei
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [5] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [6] The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience
    Wu, Fan
    Chen, Mulan
    Wang, Lili
    Li, Nani
    Wu, Xiufeng
    Chen, Xinhua
    Hong, Yi
    Li, Chongyin
    Lin, Lin
    Chen, Kan
    Huang, Weiwei
    Liu, Jian
    CURRENT CANCER DRUG TARGETS, 2024, 24 (05) : 490 - 500
  • [7] PertuzumabIn the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
    Gillian M. Keating
    Drugs, 2012, 72 : 353 - 360
  • [8] Pertuzumab In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
    Keating, Gillian M.
    DRUGS, 2012, 72 (03) : 353 - 360
  • [9] Efficacy and safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer.
    Kong, Ying
    Dong, Qi
    Jin, Peng
    Li, Yan Ming
    Ma, Li
    Liu, Yan Hai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Updated efficacy and safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer
    Kong, Y.
    Dong, Q.
    Jin, P.
    Li, M.
    Ma, L.
    Yi, Q.
    Miao, Y-E.
    Liu, J.
    Liu, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1467 - S1467
12345